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Abstract
Hek-293 cell line presents good production platform for recombinant therapeutic proteins, however little is known
about the components that contribute to the cellular control of recombinant protein production. In this study, we
generated a Hek-293 producing recombinant factor VIII (FVIII) and we evaluated the immunoglobulin-binding
protein (BiP) and phytanoil-CoA α-hydroxylase (PAHX) expression levels which are known for diminishing FVIII
production. Our analyses showed that the recombinant cell population expresses 3.1 ± 1.4 fold of BIP mRNA
(P = 0.0054) and 97.8 ± 0.5 fold of PAHX mRNA (P = 0.0016) compared to nontransduced cells. The amount of these
proteins was inversely correlated to the secreted FVIII. In conclusion, BIP and PAHX expression are augmented in
human cells producing FVIII and they antagonize the amount of therapeutic factor VIII in the cell culture.
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Introduction
Hemophilia A is a hemorrhagic disease caused by insuf-
ficient levels or complete absence of functional coagula-
tion factor VIII (FVIII) in the circulation. Hemophilic
patients show spontaneous bleeding episodes primarily
in soft tissues and joints. This clinical condition can also
cause potentially life-threatening hemorrhages in mus-
cles, internal organs and central nervous system (Ghosh
2004; Zago et al. 1987; Antunes et al. 2003).
The current treatment of hemophilic patients consists of
prophylactic or therapeutic replacement of the deficient fac-
tor by intravenous infusions of FVIII plasma-derived con-
centrates or recombinant FVIII (rFVIII). Increasingly, the
reposition therapy with FVIII concentrates from plasma is
substituted by rFVIII produced by mammalian cells culture
(Lee 1999; Neidhardt et al. 2005). This source of FVIII
brought important therapeutic improvements due to the
advantage over the safety of recombinant products com-
pared to those that are plasma-derived. During the 80s,
plasma derived products were connected to the spread of
HIV and/or hepatitis viruses among thousands of
hemophilic patients (Stanley 2006).
Recombinant coagulation factor products are already
available in the market for 20 years. So far, FVIII recom-
binant proteins are produced in murine cells CHO or
BHK (Baxter 2010; HealthCare 2009; Wyeth Pharma
Pfizer 2007). Although these products have proved to be
very similar to the FVIII derived from plasma, recom-
binant FVIII shows a pattern of nonhuman post-
translation modifications (PTM).
FVIII is one of the largest and most complex protein
in the market and is produced by recombinant DNA
technology (Jiang et al. 2002). This factor is submitted to
multiple PTM, particularly glycosylation. Incorrect
reproduction of these PTM in a nonhuman expression
system may trigger immune reactions and lead to the
formation of inhibitors against FVIII. Thus it will be es-
sential to find human cell lines to produce recombinant
FVIII with the same glycosylation pattern as the plasma
protein. The advantages of using human cell-based
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expression systems is the high similarity of PTM and the
absence of antigenic residues that commonly are present
in rFVIII from licensed hamster cell-lines like as cited
above (Durocher and Butler 2009). Some studies have
associated human HEK 293 cell with a promising poten-
tial to rFVIII production in large-scale, using serum-free
suspension technology (Picanço et al. 2007; Swiech et al.
2011).
The HEK 293 human embryonic kidney cell line is
more often used by the scientific community for the
production of recombinant proteins. This strain has
rapid growth and it is highly susceptible to transfection
and viral transduction (Durocher et al. 2002; Thomas
and Smart 2005). Furthermore, there is a commercial
adapted version of this strain suspension (Free Style
293-F Cells) which allows the production of large-scale
recombinant proteins (Invitrogen Corporation 2007).
Although many PTM are required to obtain a active
and non immunogenic FVIII, recombinant FVIII inter-
acts with a number proteins, including calreticulin,
calnexin, and immunoglobulin-binding protein (BIP),
thus a significant proportion of the FVIII molecule is
retained within ER, thereby limiting the transportation
of FVIII to the Golgi apparatus. Previous studies showed
that the over-expression of BIP inhibits FVIII secretion
(Morris et al. 1997) and the antisense RNA expression
for BIP reduces BIP levels and improves FVIII secretion
(Brown et al. 2011). Another FVIII binding protein, cor-
related negatively with FVIII expression, is phytanoyl-
CoA α-hydroxylase (PAHX). This human protein is a
peroxisomal enzyme that not only diminishes FVIII se-
cretion into culture media, but also changes FVIII-A2
intracellular distribution (Chen et al. 2001). Interactions
between FVIII and these proteins may limit FVIII pro-
ductive secretion. Therefore, the strategy for overcoming
such limitations may be known the alterations of endo-
plasmic reticulum (ER) chaperones and peroxisomal
components that might contribute to the cellular control
of recombinant protein production.
In this study, we evaluated the levels of BIP and PAHX
in clones producing FVIII with a partially deleted B-
domain (rFVIIIΔB). We found that even using a human
cell line with proper machinery to produce FVIII, when
it is forced to express high levels of recombinant FVIII,
it generates a cellular stress and increases the production
of PAHX and BIP that retains part of the FVIII
production.
Material and methods
Construction of recombinant retroviral vector
Initially, the DNA fragments of 2.29 kb and 2.09 kb re-
ferring to the heavy and the light chain of human coagu-
lation FVIII were obtained by polymerase chain reaction
(PCR) using the forward 5’- CCG CTC GAG ACC ATG
CAA ATA GAG CTC TCC ACC – 3’ and 5’-AGC TTT
GTT TAA ACT GAA TTC TGG GAG AAG CTT C-3’
and reverse primers 5’- AGC TTT GTT TAA AC CAA
AAC CCA CCA GTC TTG AAA CG −3’ and 5’- ATA
AGA ATG CGG CCG CTC AGT AGA GGT CCT GTG
CC −3’ respectively. As a positive control, plasmid
pSP64 - VIII (American Type Culture Collection-
ATCC) was used containing full cDNA the FVIII.
Each amplified DNA fragment was further cloned into
pCR®2.1-TOPO vector – (Invitrogen, Carisbad, CA,
USA) generating HC_PCR 2.1+ (vector containing FVIII
heavy chain) and LC_PCR 2.1+ (vector containing FVIII
light chain). The light chain presents into LC_PCR 2.1
was isolated by restriction endonucleases using the sites
NotI and PmeI to clone into the vector that contains
heavy chain (LC_PCR 2.1+) previously cut with the same
endonucleases. We confirmed sequences of the FVIII
light and heavy chain as well as the junction region (53
aas N-terminal of B domain and 12 aas C-terminal B do-
main) in rFVIII/HC + LC-PCR 2.1+ construct by DNA
sequencing (ABI Prism™ DNA Sequencer, Applied
Biosystems, CA, USA). The fragments related to FVIII
light and heavy chains with partially deleted B-domain
were isolated using restriction NotI and XhoI endonucle-
ase sites for cloning into pBMN-I-GFP vector previously
digested with same enzymes creating BMN-FVIIIΔB-I-
GFP. The pBMN-I-GFP vector, which expresses GFP
and contains IRES (internal ribosome entry site), was
kindly provided by Dr. Garry P. Nolan (NIH, EUA). This
construction formed NCBI NM_000132 alignment,
which indicated that the constructions were in frame.
The retroviral BMN-FVIIIΔB-I-GFP vector, that ex-
presses the partially deleted B-domain FVIII, was used
to generate recombinant cell lines.
PCR
PCR was performed with specific primers for the FVIII
heavy and light chains ( 5’- CTT GGA CAG TTT CTA
CTG - 3’, 5’- GAC GGA CAT CAG TGATTC −3’, 5’- GGT
CTT CTT TGG CAA TG - 3’, 5’- GGT GTG AAG GAG
TCT TG −3’). Reactions were performed in 25 μl of reaction
volume containing 100 ng of DNA, 1.0 U of Taq DNA poly-
merase (Invitrogen, Carisbad, CA, USA ), 50 mM KCl,
20 mM Tris–HCl, pH 8.3, 1.5 mM MgCl2, 0,2 mM each
deoxynucleotide triphosphate (dNTP), and 0.3 pmol of each
specific primer. Thermocycling was performed in the
GeneAmp PCR system 9700 (Perkin-Elmer/Cetus, Norwalk,
CT). PCR cycling conditions consisted of an initial cycle of
2 minutes at 94°C, followed by 35 cycles of 40 seconds at
94°C, 1 minute at 56 C, 2.3 minutes at 72°C, and a final ex-
tension at 72°C for 10 minutes. The amplified products were
analyzed by 1% agarose gel electrophoresis followed by eth-
idium bromide staining.
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DNA sequencing
DNA sequencing was performed using ABI Prism® Big
Dye™ Terminator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems, Foster City, CA, USA), according to
the manufacturer’s instructions, and electrophoresed,
directly with an automated apparatus ABI Prism 377
DNA Sequencer (Applied Biosystems, Foster City, CA,
USA). The electropherograms were analyzed by Se-
quence Analyzer software ABI Analysis Data Collection
version 3.3 (Applied Biosystems, Foster City, CA, USA).
The obtained sequences were aligned with the reference
sequence available on GenBanK (NM_000132) by
Sequencher software version 4.05 (Gene Codes Corp,
Ann Arbor, MI, EUA).
Cell culture
PG13/LN c8 cell line and human embryonic kidney 293
cells (Hek-293) (American Type Culture Collection –
ATCC Manassas, VA) were maintained in Dulbecco’s
modified Eagle’s medium (Gibco-BRL) supplemented
with 2 mM L-glutamine (Gibco-BRL, Gaithersburg, MD,
USA), 3.7 g/l sodium bicarbonate, 2.4 g/l buffer HEPES,
10% fetal calf serum (HyClone, Logan, UT, USA), and
100 U penicillin/streptomycin (Sigma, Grand Island, NY,
USA). All the cell lines were maintained in a humidified
incubator under 5% CO2 at 37°C.
Transfection and transduction of cells
The packaging PG13/LN c8 cell line was cultured into
100 mm plates and incubated overnight until 80% con-
fluence. The cells were further transfected with the
BMN-FVIIIΔB-I-GFP vector using LipofectAMINE™ Re-
agent kit (Invitrogen, Carisbad, CA, USA), following
manufacturer’s instructions. Four hours after transfec-
tion, cells were washed with buffer PBS (1X), reduced
volume of fresh culture medium was added and the cells
were incubated under 5% CO2 in a humidified incubator.
The viral supernatant was collected at 24, 48 or 72 hours
and used for transduction.
To infect Hek 293 cells, the supernatant with infec-
tious virus, produced by packaging PG13/LN c8 cells
after transfection, was daily collected, filtered by 45μm
filter (Millipore, Billerica, MA, USA), mixed with 5.5 μg/
μl of polybrene (hexadimethrine bromide - Sigma, MA,
USA) and incubated with Hek-293 cells for 16 hours.
This procedure was repeated three times.
Analysis and sorting of cells by fluorescent flow
cytometry
After transduction, Hek-293/BMN-FVIIIΔB-I-GFP cells
were harvested, washed in 1X PBS, centrifuged at 335 g,
resuspended in buffer 1X PBS and analyzed by flow cy-
tometry (FACsort, BD, San Jose, CA, USA) to quantify
the percentage of GFP-positive cells. GFP-positive cells
were sorted using a FACS Vantage (Becton Dickinson,
San Jose, CA, USA).
Real-time PCR
RNA was extracted from 5 × 106 cells using Trizol
(Invitrogen, Carisbad, CA, USA) and cDNA was synthe-
sized using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) using
the following reaction: 2.0 μg RNA, Random Primers
1X, RT Buffer 1X, 10 mM dNTP’s, 0.3μl RNAse OUT
and 50U MultiScribe™ MuLV reverse transcriptase in a
total volume of 20 μl and incubated at 25°C for 10 min,
37°C for 120 min. SYBR Green real-time PCR was car-
ried out using ABI Prism 7500 Sequence Detection Sys-
tem (Applied Biosystems, Boston, MA) in a total volume
of 15 μl containing 2.5 pM each specific primers
(Table 1), SYBR Green PCR Master Mix, and 2 μl of
cDNA. After initial incubations at 50°C for 2 min and
95 °C for 10 min, 40 cycles of amplification were carried
out for 15 s at 95°C followed by 1 min at 60°C. Human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as endogenous control to standardize the
amount of applied RNA and to confirm the quality of
the isolated RNA. Single-product amplification was con-
firmed by postmelting curve. Duplicate samples were
measured and averaged. Relative FVIII light and heavy
chain, BIP chaperone, and phytanoyl-CoA α-hydroxylase
(PAHX) transcription levels were measured as expres-
sion relative unit. The difference in CT values between
the analyzed genes and endogenous control reactions
(dCT) was converted into expression relative units by
setting GAPDH equal to 10 000 and dividing by 2dCT
(Albesiano et al. 2003).
Activated partial thromboplastin time (APTT)
In vitro recombinant human FVIII activity from super-
natants of transduced Hek 293 cells cultured in the pres-
ence of inducers of calcium ionophore (A-23187)
protein secretion (3 μg/ml), and Phorbol 12-myriastate
Table 1 Primers used in PCR Real-time analysis
Primer Name Primer sequence
P5 BiPH 5’- CCA ACG CCA AGC AAC CAA AG-3’
P3 BiPH 5’- CTT CTC CCC CTC CCT CTT AT-3’
P5 FytCoAH 5’- CTG TCT GGT TGT GCT CCC A-3’
P3 FytCoAH 5’- GCC TTG TTT TCC TCG TAG TCC-3’
P5 CHFVIII 5’- CAC TCT TGA TGG ACC TTG GAC-3’
P3 CHFVIII 5’- TCG TAG TTG GGG TTC CTC TG-3’
P5 CLFVIII 5’- GAT GGG AAG AAG TGG CAG AC-3’
P3 CLFVIII 5’- GTG CAA ACG GAT GTA TCG AGC-3’
P5 GAPDH 5’- GCC TCA AGA TCA TCA GCA ATG C-3’
P3 GAPDH 5’- CAT GGA CTG TGG TCA TGA GTC CT-3’
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13-acetate (PMA) (6 μg/ml) for 24 hours were quantified
by measuring the FVIII-dependent generation of throm-
bin using one stage clotting assay ATTP (Biomérieux,
Sweden). FVIII deficient plasma was used as substrate,
human plasma purified FVIII Verify – Reference plasma
– (Organon Teknika, Durham) was used as a positive
qualitative standard, and 1,000 mU was defined as
200 ng FVIII/ml or 1U as 100% of activity. For the
thrombin activation assay, conditioned medium of trans-
duced Hek 293 cells was diluted (1:5) and incubated at
room temperature. After incubation, the FVIII activity
was measured by COAG-A-MATE® XM - Organon
Teknika according to the manufacturer’s specifications.
Statistical analysis
The normality of the data was examined by Shapiro-wilk
test using R (version 3.0) p ≤ 0.05. Then, the data was
analyzed applying t-test with Mann–Whitney test or
nonparametric correlation (Spearman) test, one-tail
using the GraphPad InStat software, version 3.0
for Windows (GraphPad Software, San Diego, CA,
USA; http://tools.invitrogen.com/content/sfs/manuals/
FreeStyle_293_F_Cells_man.pdf ), with the level of sig-
nificance set at p ≤ 0.05.
Results
Construction of the BMN-FVIIIΔB-I-GFP retroviral plasmid
To generate the retrovirus bicistronic vector BMN-
FVIIIΔB-I-GFP, rFVIIIΔB was amplified by PCR using spe-
cific primers to amplify the heavy chain (domain A1, A2
plus 53 aas N-terminal of B domain) and the light chain
(domains A3, C1, C2 plus 12 aas C-terminal B domain) of
hFVIII. These DNA fragments were joined and generated
one common fragment with 4.3 kb DNA. This DNA frag-
ment was first cloned into pCR2.1-TOPO vector (Figure 1:
lanes 1, 2) and then into expression vector pBMN-I-GFP
(Figure 1: lanes 3, 4). The cloned sequence authenticity was
confirmed by DNA sequencing.
After the retroviral transduction, Hek-293/BMN-
FVIIIΔB-I-GFP cells were sorted by FACS to obtain a
cell population with high level of eGFP. Fifteen days
later, the flow cytometry analysis showed that all derived
population (Hek-293/BMN-FVIIIΔB-I-GFP 1–15) were
GFP positive and presented the proportion of GFP+ cells
higher than 40% (Table 2).
Correlation between percentage of GFP+ cells and FVIII
mRNA expression level
We evaluated the expression of the light and heavy chain of
FVIII by semi-quantitative reverse transcription-PCR in fif-
teen isolated cell population and compared with the per-
centage of GFP positive cells to assess the GFP efficiency as
a gene marker to select rFVIII cell producers. The GAPDH
gene was used as endogenous control, showing a
Figure 1 Cloning FVIIIΔB in pBMN-I-GFP. FVIIIΔB containing FVIII
heavy and light chain with B-domain partial deleted was cloned first
in pCR2.1-TOPO plasmid and after in pBMN-I-GFP. Agarose gel (1%)
stained with ethidium bromide after electrophoresis showing both
clones. Lanes 1 and 3: DNA from recombinant clones without
restriction enzyme digestion. Lane 2: XhoI/NotI digested positive
FVIIIΔB clone in pCR2.1-TOPO plasmid. Lane 4: XhoI/NotI digested
positive FVIIIΔB clone in pBMN-I-GFP plasmid. Lanes M: 1 kb DNA
ladder and lambda DNA digested with HindIII.
Table 2 Biological activity of FVIII secreted by Hek-293/
BMN-FVIIIΔB-I-GFP
Sample % of GFP expression Activity (%) IU/mL
Culture medium DMEN - 1.5 -
S. Cell pop. 01 74.0 14.0 0.1
S. Cell pop. 02 80.0 11.1 0.1
S. Cell pop. 03 76.5 10.0 0.1
S. Cell pop. 04 72.1 34.6 0.3
S. Cell pop. 05 70.0 41.9 0.4
S. Cell pop. 06 70.5 21.7 0.2
S. Cell pop. 07 68.1 1.9 0.0
S. Cell pop. 08 63.8 2.2 0.0
S. Cell pop. 09 44.3 2.9 0.0
S. Cell pop. 10 43.4 20.1 0.2
S. Cell pop. 11 44.9 4.1 0.0
S. Cell pop. 12 48.2 75.8 0.7
S. Cell pop. 13 53.6 18.5 0.1
S. Cell pop. 14 62.5 47.9 0.4
S. Cell pop. 15 48.6 37.1 0.3
Analysis of biological activity of FVIII secreted by Hek-293/BMN-FVIIIΔB-I-GFP
using TTPA assay. S Supernatant, Cell pop Cell population, Hek-293 human
embryonic kidney epithelial cells.
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homogeneous profile expression among the studied sam-
ples (SD = 0,8). As expected, we found a positive correlation
between the mRNA expression of FVIII and the percentage
of GFP+ cells selected in all Hek-293/BMN-FVIIIΔB-I-GFP
clones (r = 0.71, p = 0.0015)(Figure 2).
mRNA expression of BIP and PAHX in the Hek-293/BMN-
FVIIIΔB-I-GFP cell population
Considering that rFVIII expression in cell lines can be
modulated by proteins that interact with the FVIII mol-
ecule and limit mRNA translation, transportation into the
Golgi complex and secretion, we evaluated the mRNA ex-
pression level of two proteins that are known for interacting
with FVIII (BIP and PAHX). The real-time PCR analysis of
the 15 selected population showed an increase of 3.1 ± 1.4
fold of BIP mRNA expression on Hek-293/BMN-FVIIIΔB-
I-GFP cell population when compared to non-transfected
Hek-293 cells (p = 0.0054) (Figure 3A). We also observed
an induction of 97.8 ± 0.5 fold expression of mRNA PAHX
in the cell population producers of rFVIII (p = 0.0016) (Fig-
ure 3B). These results indicate that the overexpression of
FVIII mRNA induces BIP and PAHX expression because of
the cellular stress created by the recombinant protein.
Protein secretion of FVIII and the mRNA expression of BIP
and PAHX
To investigate the impact of the expression FVIII-ligand
proteins in the rFVIII secretion, we verified the correl-
ation between expression (BIP and PAHX) and biological
activity of the FVIII.
Among the FVIII selected population, we observe an
inversely proportional correlation between mRNA BIP
expression and the value of the biological activity
(p = 0.009 r = −0.60) (Figure 4A). Similar results were
obtained when we compared FVIII secretion to the ex-
pression levels of mRNA of PAHX, showing a negative
correlation (p = 0.042 r = −0.46) (Figure 4B).
Discussion
In this work, we used retroviral system for the expres-
sion of FVIII recombinant molecule that contains light
and heavy chains of the protein and a small segment of
the B domain. Native full-length human FVIII consists
of 2332 amino acid residues divided into the following
domains: A1-a1-A2-a2-B-a3-A3-C1-C2; the heavy chain
comprises the domains A1-a1-A2-a2-B and light chain
a3-A3-C1-C2. The chains as linked by a divalent metal
ion (Shen et al. 2008; Lenting et al. 2010). Previous re-
ports in the literature showed that B domain does not
play an important role in the biological activity protein
and can be removed without losing its function for
blood coagulation (Toole et al. 1986). rFVIII constructs
with partial deleted B domain have shown the presence
of biologically active FVIII in the supernatant of differ-
ent cell cultures (Meulien et al. 1988; Lind et al. 1995;
Figure 2 Correlation between mRNA FVIII and GFP expression
in Hek-293/BMN-FVIIIΔB-I-GFP cell population. Correlation
analysis between mRNA of FVIII heavy chain and the percentage of
GFP positive cells (p = 0.0015, r = 0.71) n = 15. Data are reported as
expression relative units (ERU). We used nonparametric correlation
(Spearman) test, one-tail and data were considered statistically
significant (p < 0.05).
Figure 3 Gene expression of mRNA of BIP and PAHX among Hek-293/BMN-FVIIIΔB-I-GFP cell population. A and B) Gene expression of
mRNA of BIP and PAHX in Hek-293/BMN-FVIIIΔB-I-GFP cells and Hek-293 non-transfected cells. Data are reported as expression relative units (ERU)
and are represented as the means ± SEM. We used nonparametric t-test (Mann Whitney), one-tail and data were considered statistically significant
(p < 0.05). The asterisks denote significant differences compared to non-transfected Hek-293 (** p < 0.01).
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Herlitschka et al. 1998; Burton et al. 1999). Another ad-
vantage is the removal of the B-domain is that it allows
nano-filtration of the recombinant protein enhancing
purity and safety. The B-domain is highly glycosylated,
but it is not essential for the pro-coagulant function of
the protein. The B domain may be important for intra-
cellular processing and trafficking during biosynthesis
(Pipe 2009). The recombinant products in the market
are produced in murine cell lines that have in their
structure the antigenic carbohydrate epitopes α-Gal and
Neu5Gc, which are absent in human-FVIII. The FVIII
production in a human cell line avoids the potential in-
corporation of non-human glycan epitopes (Kannicht
et al. 2013).
Human cell lines for the production of FVIII are
highlighted as an improvement in the treatment of
Hemophilia A. These cells have proper machinery for
PTM and secretion of FVIII. In this work, we evaluated
if the forced expression of FVIII in a human cell line
(Hek 293) can alter the expression of FVIII-ligand pro-
teins (BIP e PAHX) what can influence FVIII produc-
tion. Our work showed that the transcription levels of
mRNA of BIP and PAHX in the Hek-293/BMN-
FVIIIΔB-I-GFP were increased in relation to the non-
transfected cell. Similar results have been described by
(Becker et al. 2004) who demonstrated that FVIII mRNA
expression induce a rather moderate increase of BIP
transcription in COS cells transfected with rFVIII full
length and B-domain deleted, reflecting the cellular
stress created by the recombinant protein.
The mRNA expression levels of BIP and PAHX were
reversely proportional to the secretion level of biologic-
ally active FVIII. BIP protein is supposed to interact with
A1 domain of FVIII and decrease FVIII secretion
(Marquette et al. 1995; Dorner et al. 1992; Dorner and
Kaufman 1994). To solve this problem, other authors
(Miao et al. 2004; Srour et al. 2008) suggest the con-
struction of rFVIII molecules with mutations within the
A1 domain to reduce the interaction with BIP chaperone
protein (Miao et al. 2004), or the addition of a glycosyla-
tion site in the N terminal region of FVIII protein (Srour
et al. 2008).
PAHX mRNA has been found in specific tissues like
liver and kidney. As Hek-293 is a kidney derived cell
line, we evaluated if PAHX expression could alter FVIII
secretion. Our work shows that Hek 293 cell population
with the highest FVIII secretion levels presented low ex-
pression of mRNA PAHX. Chen et al. showed that
PAHX overexpression in BHK cells producing rFVIII is
related to 70% decrease of FVIII protein expression,
according to quantification of bands on the immuno-
blotting (Chen et al. 2001).
Many strategies have already been applied as an at-
tempt to improve FVIII secretion and to diminish the
costs of rFVIII production. The production of recombin-
ant FVIII in murine cells should be replaced by the pro-
duction in human cells. However, it is necessary to
evaluate the stress caused by the high expression of ex-
ogenous FVIII in human cells and develop strategies for
inhibiting and/or silencing proteins as BIP and PAHX.
Our work suggests the screening of BIP and PAHX
mRNA of FVIII Hek 293cell producers as a new per-
spective to improve and facilitate FVIII production.
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